- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04096443
Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis
A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific aims are to:
- Determine the tolerability of a single dose of 30 capsules in a group of adults with MS
- Determine whether any unexpected outcomes arise in participants who successfully complete an FMT procedure consisting of a single dose of 30 capsules
- Determine whether successfully completed FMT leads to engraftment of donor microbiome in participants
- If the FMT leads to engraftment of donor microbiome in participants, determine whether participants revert back to previous microbiome profiles, and if so, at what time point
- Determine whether engrafted species following the FMT, if detected, result in any changes in immune or metabolomic parameters relative to baseline
- Determine whether the FMT has any adverse impact, relative to baseline, on study participants' self-reported levels of fatigue, mental well-being, and health-related qualify of life
- Determine whether the FMT has any adverse impact, relative to baseline, on study participants' neurological status, relative to baseline
The study population will consist of adults with clinically definite MS who are currently untreated with any disease-modifying therapy or are being treated with glatiramer acetate or interferon beta. The research team will offer study participants a single FMT procedure in the form of 30 oral capsules which contain fecal material. Study participants will visit Griffin Hospital facilities 8 times. The first visit will involve a clinical screening. Of the 7 remaining visits, 6 will involve data collection and one will involve the FMT procedure.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Joseph B Guarnaccia, MD
- Phone Number: 203-732-1290
- Email: mstreatmentcenters@griffinhealth.org
Study Contact Backup
- Name: Rockiy G. Ayettey, MS
- Phone Number: 203-732-1125
- Email: rockiy.ayettey@yalegriffinprc.org
Study Locations
-
-
Connecticut
-
Derby, Connecticut, United States, 06418
- Griffin Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of clinically definite multiple sclerosis (CDMS) by 2017 McDonald Criteria
- Ages between 18 and 55 years, inclusive;
- Expanded Disability Status Score (EDSS) between 1.0 and 6.5.
- Currently untreated with any disease-modifying therapy (DMT) or currently being treated with glatiramer acetate or interferon beta.
- Ability to travel to Griffin Hospital for 8 visits over a 5-month period
Exclusion Criteria:
- Inability to give consent;
- Non-fluency in English;
- Inability to adhere to the protocol;
- Inability (e.g., dysphagia) to or unwillingness to swallow capsules;
- Active gastrointestinal infection at the time of enrollment;
- Use of antibiotics or corticosteroids within three months of study entry;
- Requiring or anticipating antibiotic use during the four weeks after study entry;
- MS relapse within one month of study entry;
- Previous use of any of the following FDA-approved disease-modifying drugs within 12 months of study entry, including natalizumab, fingolimod, siponimod, ozanimod, teriflunomide, diroximel, ocrelizumab, ofatumumab, and/or dimethyl fumarate; or any of the following off-label therapies, including rituximab and cyclophosphamide;
- Any previous use of the following FDA-approved DMTs, including mitoxantrone, alemtuzumab, and cladribine;
- IV immunoglobulin or plasma exchange within six months prior to study entry;
- Known or suspected toxic megacolon and/or known small bowel ileus;
- Major gastrointestinal surgery (e.g., significant bowel resection) within 3 months prior to enrollment (this does not include appendectomy or cholecystectomy);
- History of total colectomy or bariatric surgery;
- Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy;
- Anticipated life expectancy of less than six months;
- Concomitant other known autoimmune diseases;
- Concomitant pulmonary, cardiac, gastrointestinal (except as noted above) (Crohns, Colitis, inflammatory bowel, intestinal blockage), hepatic, dermatological or genitourinary disease.
- Moderate to severe dysphagia;
History of alcohol abuse, as defined by the following criteria:
Men: 5 or more alcoholic beverages per session or day, or 15 or more per week; Women: 4 or more alcoholic beverages per session or day, or 8 or more per week;
- History of illicit drug abuse, e.g., of cocaine, heroin, PCP, and/or narcotic substances;
- Grade 1 or greater lymphopenia, as measured at baseline/clinical screening;
- Liver Function Tests (LFTs) greater than 1½ times upper limits of normal, as measured at baseline/clinical screening;
- History of use of FMT or microbiome-based products (excluding probiotics) at any time, excluding this study;
- History of severe anaphylactic or anaphylactoid food allergy;
- History of solid organ transplantation;
- Risk for Cytomegalovirus (CMV) or Epstein Barr virus (EBV) associated disease (at investigator's discretion, e.g., immunocompromised and negative (immunoglobulin gamma) IgG testing for CMV or EBV);
- Women who are pregnant, lactating, planning to become pregnant, and/or not using an effective method of contraception (women of childbearing potential will undergo a pregnancy test, and will be excluded from the study if results are positive);
- Any allergies to neomycin or similar antibiotics such as amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), paromomycin (Humatin, Paromycin), streptomycin, or tobramycin (Nebcin, Tobi);
- Any condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the study results.
- Household contacts, including children under the age of 5 years, pregnant women, any person with an immunocompromised condition or on medications causing immunosuppression or persons 70 years or older;
- Failure to document a COVID-19 vaccine series at least two weeks prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Fecal microbial transplant capsules
|
Oral fecal microbial transplant capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in engraftment of donor microbiome in stool samples
Time Frame: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
Evidence of engraftment as measured by 16s rRNA microbiome sequencing
|
Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in immune markers in blood samples assessed using assays of lymphocyte phenotyping and intracellular cytokines
Time Frame: Pre-FMT and 2 time points post-FMT (40-45 days, 100-110 days)
|
Phenotyping will be performed: for T cells - TCRβ, TCRγ, CD4, CD8, CD25, CD44, CD62L, CD69, PD1, CTLA4; for B cells - B220, CD19, CD21, CD23, CD1d, CD5, IgA, IgG1, IgG2a(c), IgG2b; for DCs - CD11c, CD11b, BDCA1, CD8, CD103, CD205 and CD86.
The intracellular cytokine (ICC) panel will be IL-6, IL-10, IL-12, IL-17, TNFα, and IFNγ.
|
Pre-FMT and 2 time points post-FMT (40-45 days, 100-110 days)
|
Change in neurological status using Kurtzke Functional Systems Scale (FSS)
Time Frame: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
The FSS uses a set of single-item ordinal clinical rating scales to rate levels of function in seven domains (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, and cerebral/mental).
Each single item scale ranges from 0 to 5 or 6 (0 = "normal;" 5 or 6 represents the worst level of function; and 9 = "unknown").
For each single item scale, scores representing the highest level of function are as follows: pyramidal: 6 = "quadriplegia"; cerebellar: 5 = "unable to perform coordinated movements due to ataxia"; brainstem: 5 = "inability to swallow or speak"; sensory: 6 = "sensation essentially lost below the head"; bowel and bladder: 6 = loss of bowel and bladder function"; visual: 6 = "grade 5 plus maximal visual acuity of better eye of 20/60 or less"; cerebral/mental: 5 = "dementia or chronic brain syndrome - severe or incompetent."
The ratings are used in conjunction with observations and information concerning gait and use of assistive devices to rate the EDSS.
|
Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
Change in neurological status using Kurtzke Expanded Disability Status Scale (EDSS)
Time Frame: Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS) in half-point increments.
|
Pre-FMT and 4 time points post-FMT (3-7 days, 10-15 days, 40-45 days, 100-110 days)
|
Change in self-reported health-related quality of life assessed using the Health Status Questionnaire Short-Form 36 (SF-36)
Time Frame: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
The SF-35 has 36 questions.
It has a single item covering change in health status over the last year and 8 multi-item scales.
The scoring system is relatively complex and generates 8 subscales and 2 summary scores.
The 8 subscales are: physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role-limitations due to emotional problems, and mental health.
Two summary scales (Physical and Mental) have been derived using factor analytic methods.
Scales are set up so that a higher score indicates better health.
To achieve this, responses on 10 items are recoded before being added to other items on the same scale.
Raw scale scores are then transformed to a 0-100 scale.
|
Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
Change in self-reported mental health status assessed using Mental Health Inventory (MHI)
Time Frame: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
The MHI consists of 18 items and assesses several domains of mental health.
The scoring system generates 4 subscale scores (Anxiety, Depression, Behavioral Control, and Positive Affect) and 1 total score.
The subscale and total scores range from 0-100, with higher scores indicating better mental health.
|
Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
Change in self-reported levels of fatigue assessed using Modified Fatigue Impact Scale (MFIS)
Time Frame: Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
The MFIS provides an assessment of the effects of fatigue on physical, cognitive, and psychosocial function.
It consists of 21 items.
The items be aggregated into 3 subscales (Physical, Cognitive, and Psychosocial), as well as into a total MFIS score.
All items are scaled so that higher scores indicate a greater impact of fatigue on a patient's activities.
The physical subscale can range from 0-36.
The cognitive subscale can range from 0-40.
The psychosocialsub scale can range from 0-8.
The Total MFIS score can range from 0-84.
|
Pre-FMT and 3 time points post-FMT (10-15 days, 40-45 days, 100-110 days)
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Day of FMT procedure and 5 time points post-FMT (1 day, 3-7 days, 10-15 days, 40-45 days, 100-110 days), or any time the study team is contacted by subjects who report adverse side effects
|
Measured by subject's ability to consume capsules as directed without vomiting or adverse side effects (as opposed to mild side effects)
|
Day of FMT procedure and 5 time points post-FMT (1 day, 3-7 days, 10-15 days, 40-45 days, 100-110 days), or any time the study team is contacted by subjects who report adverse side effects
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joseph B Guarnaccia, MD, Griffin Hospital
- Principal Investigator: Frederick Browne, MD, Griffin Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Fecal microbial transplant (FMT)
-
MemorialCare Health SystemMemorial Medical Center FoundationCompletedClostridium Difficile ColitisUnited States
-
Children's Hospital Los AngelesActive, not recruiting
-
VA Office of Research and DevelopmentCompleted
-
Stony Brook UniversityCompletedUlcerative Colitis | Clostridium Difficile Infection | Indeterminate ColitisUnited States
-
University of PennsylvaniaTerminatedFecal IncontinenceUnited States
-
Stony Brook UniversityCompleted
-
University of AlbertaThe Weston A. Price FoundationCompleted
-
Meir Medical CenterTerminated
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; The Broad FoundationCompletedCrohn's DiseaseUnited States
-
Children's Hospital Los AngelesActive, not recruitingUlcerative ColitisUnited States